Belvedere Trading’s BridgeBio Pharma BBIO Stock Holding History

Belvedere Trading’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-11,316	Closed	-$311K	–	709
2024 Q4	$311K	Buy	11,316 +1,905	+20%	+$49.2K	﹤0.01%	322
2024 Q3	$240K	Sell	9,411 -243	-3%	-$6.38K	﹤0.01%	313
2024 Q2	$245K	Sell	9,654 -5,323	-36%	-$146K	﹤0.01%	314
2024 Q1	$463K	Sell	14,977 -12,094	-45%	-$411K	﹤0.01%	166
2023 Q4	$1.09M	Sell	27,071 -2,658	-9%	-$79.8K	﹤0.01%	91
2023 Q3	$784K	Buy	29,729 +16,050	+117%	+$455K	﹤0.01%	89
2023 Q2	$235K	Sell	13,679 -18,910	-58%	-$285K	﹤0.01%	275
2023 Q1	$540K	Buy	+32,589	New	+$380K	﹤0.01%	138
2022 Q1	–	Sell	-7,660	Closed	-$79K	–	475
2021 Q4	$79K	Buy	+7,660	New	+$324K	﹤0.01%	327

Other funds holding BBIO

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Belvedere Trading's BBIO Position: Q1 2025 in Review

Belvedere Trading sold out of BridgeBio Pharma (BBIO) in Q1 2025, closing a stake of 11,316 shares — an estimated $311K sold.

Belvedere Trading first reported a position in BBIO in Q4 2021 and held it in 9 quarters. The position peaked at $1.09M in Q4 2023. 304 funds tracked by Wall St. Rank hold BBIO as of Q1 2025.

Belvedere Trading reported no remaining BridgeBio Pharma position as of Q1 2025 after selling out during the quarter.
Belvedere Trading sold 11,316 BridgeBio Pharma shares in Q1 2025, an estimated $311K.
Belvedere Trading first reported a position in BridgeBio Pharma in Q4 2021 and held it in 9 quarters.
Belvedere Trading's BridgeBio Pharma position peaked at $1.09M in Q4 2023.
304 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2025.

Based on Belvedere Trading's 13F filing for Q1 2025, filed 9 May 2025.